Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06662786 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Study acronym: OrigAMI-2
StatusRecruiting
PhasePhase 3
Started2024-10-18
View on ClinicalTrials.gov ↗
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.

Amendment history 1 change detected by DataLookout

2026-04-14
Trial sites expanded: 231 → 234 locations
Trial Details
NCT Number NCT06662786
Lead Sponsor Janssen Research & Development, LLC
Conditions Colorectal Neoplasms
Enrollment 1,000 participants
Start Date 2024-10-18
Primary Completion 2028-12-15 (estimated)
Study Completion 2032-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-28